39,349 Shares in PDS Biotechnology Co. (NASDAQ:PDSB) Acquired by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PDS Biotechnology Co. (NASDAQ:PDSB) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 39,349 shares of the company’s stock, valued at approximately $115,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.11% of PDS Biotechnology as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after purchasing an additional 82,135 shares in the last quarter. Blair William & Co. IL lifted its stake in PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after acquiring an additional 81,743 shares during the last quarter. Inspirion Wealth Advisors LLC grew its position in PDS Biotechnology by 5.5% in the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock worth $1,406,000 after acquiring an additional 18,383 shares in the last quarter. Tempus Wealth Planning LLC acquired a new position in shares of PDS Biotechnology during the 2nd quarter worth $55,000. Finally, Ground Swell Capital LLC bought a new position in shares of PDS Biotechnology during the 2nd quarter valued at $67,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Price Performance

PDSB opened at $3.37 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. The stock has a market capitalization of $123.61 million, a P/E ratio of -2.48 and a beta of 1.88. The company’s 50 day simple moving average is $3.25 and its 200-day simple moving average is $3.37. PDS Biotechnology Co. has a one year low of $2.53 and a one year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same period in the prior year, the firm earned ($0.37) EPS. Sell-side analysts anticipate that PDS Biotechnology Co. will post -1.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a report on Tuesday, September 17th. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. Finally, B. Riley decreased their price objective on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, June 12th. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.